Endocyte Receives DSMB Recommendation for Continuation of Vintafolid/Docetaxel Combo
October 11, 2013 at 07:46 AM EDT
Endocyte, Inc. (Nasdaq: ECYT ), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced the outcomes of the planned independent Data Safety Monitoring Board (DSMB) review of the interim futility analysis for the Phase 2b